NCT04832672已完成不适用
The Optimal Sequence of Intracranial Radiotherapy Compared to Systematic Tyrosine Kinase Inhibitors for Gene-driven Brain Metastases in Targeted Treatment Era
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 570
- 试验地点
- 1
- 主要终点
- Intracranial progression-free survival
研究概览
简要总结
The investigators conducted a single institutional, retrospective cohort study to demonstrate the appropriate treatment strategy of upfront intracranial radiotherapy or upfront targeted therapy in patients with brain metastases, including an assessment of its feasibility and toxicity.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Had histologically proven primary cancer.
- •Had newly diagnosed brain metastases in contrast-enhanced MRI.
- •Brain metastases focus should be measurable.
- •All the patients should safely receive radiotherapy and/or systematic tyrosine kinase inhibitors.
- •Karnofsky performance score (KPS) ≥60 or KPS ≥40, but only caused by brain metastases.
排除标准
- •Patients with prior intracranial local treatments, such as surgery and radiotherapy without dose prescription in detail
- •Patients with leptomeningeal metastases at first diagnosis.
- •Had synchronous or metachronous malignancies that might affect survival.
- •Had severe systemic diseases, abnormal conditions that might lead to incoordinate behavior during the implementation of clinical measures.
- •Had incomplete sociodemographic and/or clinicopathologic baseline data
结局指标
主要结局
Intracranial progression-free survival
时间窗: The interval from the start of initial intracranial treatment to first documented intracranial progression, or date of death from any cause, whichever came first, assessed up to 3 to 5 years
The survival time of patients before any intracranial progression
次要结局
- Brain metastasis-specific survival(The interval from the start of initial intracranial treatment to death from brain metastases or censored on the last follow-up, whichever came first, assessed up to 3 to 5 years)
- Overall survival(The time from the date of initial intracranial treatment until death from any cause or censored on the last follow-up, whichever came first, assessed up to 3 to 5 years)
研究者
Jianping Xiao
Professor
Chinese Academy of Medical Sciences
研究点 (1)
Loading locations...
相似试验
招募中
不适用
A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast CancerAdvanced Breast CancerNCT06776861Cancer Institute and Hospital, Chinese Academy of Medical Sciences150
尚未招募
2 期
Clinical Study of Radiotherapy Combined With Nedaplatin Contrast and Cisplatin for the Treatment of Locally Advanced Head and Neck Squamous CarcinomaHead and Neck Squamous CarcinomaNCT05039606Guiyang Medical University164
已完成
3 期
Radiotherapy or Imiquimod in Complex Lentigo MalignaLentigo MalignaNCT02394132Melanoma and Skin Cancer Trials Limited126
招募中
不适用
Ablative Radiosurgery vs Stereotactic RT in 5 Fractions With SIB for Oligometastatic Bone LesionsOligometastatic DiseaseNCT05679427IRCCS San Raffaele307
尚未招募
2 期
Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPCCarcinoma, Pancreatic DuctalNCT06573398Ruijin Hospital20